Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q1 2026
Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.1B for the first quarter 2026 (Q1 2026), +19% from a year earlier and -11% from the quarter before. Operating margin was 31.5%, net earnings $293M (27.4% of revenue).
Jazz Pharmaceuticals, Q1 2026: revenue $1.1B (+19% year over year), operating margin 31.5%, net earnings $293M, operating cash flow $408M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1B | -11% | +19% |
| Operating profit | $337M | +32% | — |
| Net earnings | $293M | +44% | — |
| Operating cash flow | $408M | +13% | -5% |
| Free cash flow | $388M | +12% | -7% |
What changed
Revenue was $1.1B in Q1 2026, up 19% year over year and down 11% from the previous quarter. Sleep was the largest line at 41% of revenue. Sleep added $0.06B year over year (up 15%), 34% of the total change. High-sodium oxybate AG royalty revenue declined 26%.
Operating profit was $0.34B, a 31.5% margin (up 37.7 points year over year). Total costs fell 23% while revenue rose 19%. Net earnings were $0.29B. The effective tax rate was 2.0%.
Operating cash flow was $0.41B (down 5% year over year), 139% of net earnings. Non-cash charges added back $0.18B of depreciation and amortization and $0.07B of share-based compensation. Working capital and other items used $0.14B. Capital expenditures of $0.02B left free cash flow of $0.39B.
Questions
What was Jazz Pharmaceuticals' revenue in the first quarter 2026?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.1B for the first quarter 2026 (Q1 2026), +19% from a year earlier and -11% from the quarter before.
Was Jazz Pharmaceuticals profitable in the first quarter 2026?
Operating profit was $337M (31.5% of revenue) and net earnings $293M.